About the Company
lumos pharma is an clinical stage biotechnology company focused on developing therapeutics for rare diseases
Exchange
NASDAQ
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $LUMO News
Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call Transcript
Operator: Good afternoon and welcome to Lumos Pharma’s 2023 Fourth Quarter and Year End Conference Call. Currently all ...
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024Previously Announced Topline Data from Phase 2 ...
Analysts Are Bullish on Top Healthcare Stocks: Lumos Pharma (LUMO), Arcturus Therapeutics (ARCT)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lumos Pharma (LUMO – Research Report), ...
Lumos Pharma FY 2023 Earnings Preview
Lumos Pharma (NASDAQ:LUMO) is scheduled to announce FY earnings results on Thursday, March 7th, after market close. The consensus EPS Estimate is -$3.97 and the consensus Revenue Estimate is $1.22M ...
2 Biotech Industry Vets to Lead AxoSim Board
Dale Pfost and David WeinerNEW ORLEANS ─ Dale Pfost and David Weiner have been appointed co-chairs of AxoSim’s board of ...
Andreessen Horowitz nears $7 billion funding haul for growth and sector-focused funds, sources say
Andreessen Horowitz, one of the most well-known venture capital funds, is moving closer to raising nearly $7 billion for multiple funds across investment stages with a sector-focus approach, sources ...
Retailer Cencosud sees LatAm 'recovery' in 2024
(Reuters) -Chilean retailer Cencosud will have a "recovery year" in Latin America in 2024, particularly in the first half, ...
India's Aditya Birla Capital to merge with financial unit
India's Aditya Birla Capital said on Monday it will merge its unit Aditya Birla Finance with the parent and turn into an operating non-banking financial company from an holding company.
Q4 2023 Lumos Pharma Inc Earnings Call
John McKew; President and Chief Scientific Officer; Lumos Pharma Inc Pisit Pitukcheewanont; Chief Medical Officer; Lumos Pharma Inc Leland Gershell; Analyst; Oppenheimer & Co. Inc Edward White; ...
Lumos Pharma, Inc.: Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in ...
Loading the latest forecasts...